STRATA Skin Sciences, Inc. (SSKN)

Over the past six months, STRATA Skin Sciences' stock has declined significantly. Key events impacting the stock include the Q3 2025 earnings report, which missed analysts' estimates, and the CMS recognition of expanded CPT codes. News of the upcoming Q2 2025 earnings release led to a moderate positive market reaction. Strategic moves and a favorable turn in a lawsuit against LaserOptek also impacted the stock.

Information specifically detailing the demand seasonality for STRATA Skin Sciences' products and services is not readily available. The available data primarily discusses stock seasonality, indicating that buying SSKN stock in November has the highest probability of a positive return, while March has the lowest. This refers to stock market trends rather than the seasonal demand for dermatological treatments or equipment.

STRATA Skin Sciences, Inc. (SSKN) is a medical technology company focused on developing and commercializing products for dermatological disorders. The company's primary products include the XTRAC® excimer laser and VTRAC® lamp systems, used for conditions like psoriasis and vitiligo. STRATA also offers the TheraClear®X Acne Therapy System and a non-invasive Ultrasound Therapeutic System (UTS) for skin laxity and fat reduction. The company operates through Dermatology Recurring Procedures and Dermatology Procedures Equipment segments.

STRATA Skin Sciences primarily generates revenue from the United States. The company also distributes its products internationally through partners in Europe, the Middle East, Asia, Australia, South Africa, and Central and South America.

STRATA Skin Sciences' brand reputation has been influenced by financial challenges and strategic initiatives. The company has faced financial struggles, including slumping sales and ongoing operating losses. Despite these difficulties, the company has undertaken strategic moves to improve its standing, including increasing direct-to-consumer marketing and actively pursuing broader insurance reimbursement. A favorable development in a lawsuit against a competitor, LaserOptek, could provide future financial benefits and positively impact its reputation.

STRATA Skin Sciences, Inc. has notable institutional and insider ownership. As of September 30, 2025, the company had 27 institutional owners holding a total of 1,169,817 shares. Insider ownership concentration was approximately 89.27% of the company's equity base as of January 6, 2026.